Outcomes-Based Pricing: Can It Facilitate The Study Of Precision Dosing?
Roche's Richard Peck says adoption of outcomes-based pricing in the US could be powerful incentive to study precision dosing, although he also calls on drugmakers to put out scientific examples.
You may also be interested in...
New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development
Robert Temple, the FDA's voice of institutional memory, believes drug regulation has quietly entered a third era: the “Age of Individualization.” Unlike the prior eras of safety and efficacy, there is no milestone legislation to set the ground rules.
Medicare Weighing Higher Add-On Payments For New Drugs, Including CAR-T
Change would increase maximum new technology add-on payments from 50% to 65% of costs.
Value-Based Contracting Bill Aims For Bipartisan Political Support
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.